So-called GLP-1 supplements, named to echo the class of glucagon-like peptide-1 agonist drugs that includes Wegovy and Zepbound, are likely to be ineffective for weight loss
7 If these treatments do not improve glycemia or if patients stop producing insulin, doctors may prescribe insulin in combination with other drugs to be injected directly by patients
The Phase 3 TRIUMPH-4 trial (NCT05869903) enrolled adults with obesity and knee osteoarthritis
Survodutide (BI 456906) is another promising dual GLP-1R/GCGR agonist under development for the treatment of T2D, obesity, and NASH
1 The most common side effects affected the gut, as with other GLP-1 medications
The tissue directly around the navel is thinner and more vascular, which increases bruising risk and can lead to inconsistent absorption